期刊
JOURNAL OF CLINICAL VIROLOGY
卷 69, 期 -, 页码 74-77出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcv.2015.05.023
关键词
B-cell non-Hodgkin's lymphoma; Difficult-to-treat; Direct-acting antiviral agent; Hepatitis C virus; Sofosbuvir
类别
资金
- Gilead Sciences Ltd.
We report on the first well-tolerated and successful use of sofosbuvir-based therapy in a patient in whom chronic infection with hepatitis C had preceded the development of B-cell non-Hodgkin's lymphoma. The patient had previously failed numerous attempts to clear the hepatitis C virus with traditional antiviral schedules. We demonstrate that sofosbuvir-based therapy resulted in cure of hepatitis C in a patient who had relapsed during combination therapy with an NS5A inhibitor, an NS3 protease inhibitor and ribavirin, as well as treatment failures to multiple courses of interferon-based therapy. This report also suggests that eradication of hepatitis C virus may result in the short-term prevention of B-cell non-Hodgkin's lymphoma relapse. The findings from our case require further validation in future cohorts of patients. (C) 2015 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据